Amgen nabs another PCSK9 exclusive, this time with giant CVS

Amgen's ($AMGN) PCSK9 med Repatha and Sanofi ($SNY) and Regeneron's ($REGN) competitor Praluent may have both nabbed coverage from top PBM Express Scripts ($ESRX). But now, Amgen has inked an exclusive pact with the giant's archrival, CVS ($CVS). It's the second exclusive Amgen has grabbed for the cholesterol fighter this month; the biotech also negotiated a pay-for-performance deal with the health plan Harvard Pilgrim, gaining an exclusive spot on the payer's formulary in return for an upfront discount and future rebates if Repatha doesn't perform as outlined. More from FiercePharma

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.